Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,378,474

« Back to Dashboard

Summary for Patent: 5,378,474

Title: Sustained release pharmaceutical composition
Abstract:The present invention relates to a pharmaceutical pellet composition having a core element including at least one highly soluble active ingredient and a core coating which is partially soluble at a highly acidic pH. The pharmaceutical composition provides a slow release of active ingredient at a highly acidic pH and provides a constant, relatively faster rate of release at a more alkaline pH such as that of the intestine. Oral administration of the pharmaceutical pellet composition of the present invention to a patient is effective to deliver to the blood levels of active ingredient within the therapeutic range and to maintain such levels over an extended period of time.
Inventor(s): Morella; Angelo M. (Campbelltown, AU), Fisher; Mark C. (Birkenhead, AU)
Assignee: F. H. Faulding & Co. Limited (Parkside, AU)
Application Number:08/021,276
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,378,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPJ2192Jan 06, 1989

International Patent Family for Patent: 5,378,474

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria167629► Subscribe
Australia617573► Subscribe
Australia4773290► Subscribe
Canada2007181► Subscribe
Germany69025208► Subscribe
Germany69032445► Subscribe
Denmark0377518► Subscribe
European Patent Office0377518► Subscribe
Denmark0609961► Subscribe
Austria133862► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: